IngredientsCoenzyme Q10 (CoQ10), also known as ubiquinone, is a fat-soluble, vitamin-like molecule naturally present in every cellular membrane within our bodies. It is also known as Coenzyme Q, CoQ, CoQ10, Ubiquinone, Ubiquinone-Q10, Ubidecarenone, or Vitamin Q10. Its molecular structure was determined in 1958 to be 2,3-dimethoxy-5-methyl-6-decaprenil-1,4-benzoquinone.
The structure of CoQ10 consists of a benzoquinone moiety and an isoprenoid side chain, with the "10" referring to the number of isoprenyl chemical subunits in its tail. The various types of Coenzyme Q can be distinguished by the number of isoprenoid side-chains they have. The most common Coenzyme Q in human mitochondria is CoQ10; the "10" refers to the number of isoprene repeats.
CoQ10 exists in at least three distinct chemical entities: ubiquinol (reduced state product), semiquinone radical (one-electron oxidation product), and ubiquinone (two-electron oxidation product). Single electron transfer redox reactions of the CoQ head group allow CoQ to cycle through the oxidized (CoQ), radical (CoQHβ’), and fully reduced (CoQH2) forms. This redox activity allows CoQ to function as a cofactor for numerous enzymes, relay electrons in the electron transport chain (ETC), and act as an antioxidant.
CoQ10 was first identified in 1940 and isolated from the mitochondria of the beef heart in 1957. Its biological presence was found ubiquitously in the body and because of its ubiquitous nature, CoQ10 came to be known as ubiquinone. In the early 1980s, Ernster from Sweden revealed that the vitamin-like CoQ10 has the capacity of antioxidation and scavenging free radicals, and in 1972 Harman elaborated on the relationship between mitochondrial function and aging.
CoQ10 is naturally present in small amounts in a wide variety of foods, but levels are particularly high in organ meats such as heart, liver, and kidney, as well as beef, soy oil, sardines, mackerel, and peanuts. CoQ10 is most abundant in fish, chicken, pork, beef, and other muscle meats, liver and other animal organs, and some bee pollens. Plant foods contain less of this vital nutrient than animal foods, with avocado, broccoli, spinach, peanuts, pistachios, and dates providing the most. Being heat-sensitive, CoQ10 is vulnerable to cooking. Total dietary CoQ10 intake is about 5 mg/day.
CoQ10 production begins with the head group precursor 4-hydroxybenzoate (4-HB), derived from tyrosine, and tail subunit IPP, derived from the mevalonate pathway. Following tail polymerization and head group attachment, CoQ10 intermediates are processed through a series of head group modifications to yield mature CoQ. The level of CoQ10 is highest in organs with high rates of metabolism such as the heart, kidney, and liver (114, 66.5, and 54.9 ΞΌg/g tissue, respectively), where it functions as an energy transfer molecule.
CoQ10 does not originate from a botanical or traditional herbal medicine tradition, as it is a molecule discovered by modern biochemical science rather than through ethnobotanical use. It was first identified in 1940 and isolated from the mitochondria of beef heart in 1957. Following its structural characterization in the late 1950s and early 1960s, CoQ10 was rapidly adopted in clinical medicine, particularly in Japan.
CoQ10 is used extensively as a nutritional supplement as well as a pharmacological active agent. It has wide use and acceptance in the treatment of cardiovascular disease in traditional as well as alternative medicine. It is used in treating ischemic heart disease, chronic heart failure, toxin-induced cardiomyopathy, hypertension, and hyperlipidemia. Japan was among the first countries to approve CoQ10 as a prescription drug for heart failure, and it entered clinical use there in the 1970s and 1980s before becoming widely available as an over-the-counter supplement globally.
CoQ10 is crucial for efficiently transferring electrons within the mitochondrial oxidative respiratory chain and producing adenosine triphosphate (ATP). It functions as the only non-protein component of the electron transport chain (ETC). This unique characteristic enables CoQ10 to move and transfer electrons between flavoproteins and cytochromes. Each pair of electrons processed by the ETC must first interact with CoQ10, which is considered the central rate-limiting factor for the mitochondrial respiratory chain. Therefore, CoQ10 plays an essential role in adenosine triphosphate (ATP) or biological energy production.
Coenzyme Q10 is one of the most significant lipid antioxidants, which prevents the generation of free radicals and modifications of proteins, lipids, and DNA. As an antioxidant, CoQ10 functions within cell membranes to neutralize potentially harmful free radicals and other oxidants, providing antioxidant backup for vitamin E in whole-cell protection. The blood lipoproteins that transport cholesterol and other fat-soluble nutrients also contain CoQ10, protecting against oxidative breakdown.
CoQ10 itself is a natural antioxidant produced by the cells, which can inhibit mitochondrial peroxidation and help maintain the structural integrity of biological membranes. CoQ10 is located in membranes that are in close proximity to the unsaturated lipid chains, acting as a primary scavenger of free radicals. The concentration of CoQ10 in many such membranes is high, about 3 to 30 times more than the tocopherol content.
CoQ10 can potentially increase the production of vital antioxidants, such as superoxide dismutase, an enzyme that effectively mitigates vascular oxidative stress in individuals with hypertension. In addition, CoQ10 lowers lipid peroxidation levels by diminishing pro-oxidative compounds. Furthermore, CoQ10 can improve blood flow and safeguard blood vessels by preserving nitric oxide.
CoQ10 exists in two interconvertible redox states: ubiquinone (oxidized) and ubiquinol (reduced). Structurally, the only difference is two hydroxyl groups on the quinone ring head β ubiquinol carries them, ubiquinone does not. The body continuously cycles between the two states: ubiquinol donates electrons during its antioxidant function and becomes ubiquinone, then accepts electrons to return to ubiquinol. Approximately 95% of circulating CoQ10 in healthy adults is already in the ubiquinol form regardless of which form is supplemented.
Optimal production of CoQ10 occurs around 25 years of age, after which production steadily declines, with the production level at age 65 being approximately 50% of that at age 25. It is well known that tissue CoQ10 levels decrease with age; for example, greater than 30% and 50% decreases in CoQ10 were observed at the ages of 40 and 80, respectively, in human heart.
CoQ10 levels decline in some tissues in humans and rodents during aging, and CoQ10 supplementation has shown benefits as an anti-aging agent, especially under conditions associated with increased oxidative stress. Depletion of the levels of this molecule during aging can aggravate mitochondrial dysfunction, accelerating the progression of aging or age-associated diseases. Evidence indicates that the reduction of CoQ10 levels during aging can be associated with cardiovascular disease, type II diabetes, and metabolic disease.
In addition to the effect of aging, CoQ10 levels are also reduced by certain prescribed drugs (particularly statins), and in a variety of diseases. CoQ10 levels can be severely reduced in a group of mitochondrial diseases called CoQ deficiencies, which are clinically and genetically heterogeneous disorders characterized by a decrease in the levels of CoQ in tissues or cells. If the deficiency is caused by pathogenic mutations in the genes required for CoQ10 biosynthesis, it is classified as primary CoQ10 deficiency. Secondary CoQ10 deficiencies are caused by mutations in genes unrelated to CoQ biosynthesis or are derived from other physiological processes or pharmacological treatments.
Primary CoQ10 deficiency is a rare autosomal recessive disorder caused by gene defects involved in CoQ biosynthesis, with clinical features of steroid-resistant nephrotic syndrome, sensorineural hearing loss (SNHL), optic atrophy, retinopathy, and encephalopathy. CoQ10 replacement therapy is indicated for this rare disorder.
Patients with heart failure (HF) show CoQ10 deficiency; therefore, a number of clinical trials investigating the effects of CoQ10 supplementation in HF have been conducted. In patients with HF, CoQ10 levels are inversely associated with functional status and with the severity of HF symptoms such as fatigue, exercise tolerance, and dyspnea. In a sample of 43 HF patients with heterogeneous etiology, endomyocardial biopsies showed that myocardial CoQ10 levels are inversely related to NYHA functional class: higher CoQ10 levels were observed in less compromised patients (NYHA class I and II); conversely, more compromised HF patients (NYHA class III and IV) had significantly lower myocardial CoQ10 levels.
Numerous trials during the past 30 years examining CoQ10 in patients with HF have been limited by small numbers and lack of contemporary HF therapies. The recent publication of the Q-SYMBIO randomized controlled trial demonstrated a reduction in major adverse cardiovascular events with CoQ10 supplementation in a contemporary HF population. The Q-SYMBIO trial showed that CoQ10 probably reduces the risk of cardiovascular mortality (9% in the CoQ10 group versus 16% in the control group; P = 0.039) at 106 weeks, with a number needed to treat for benefit (NNTB) of 15. Mortensen 2014 also reported on major cardiovascular events (defined as unplanned hospital stay resulting from worsening heart failure, cardiovascular death, mechanical assist implantation, or urgent cardiac transplantation). There were fewer cardiovascular events in the CoQ10 group compared to the control group (15% in CoQ10 group versus 26% in control group; P = 0.005) at 106 weeks. CoQ10 was also superior to control in time-to-event analysis for cardiovascular events (HR 0.50; 95% CI 0.32 to 0.80; P = 0.003).
The largest randomized trial to date (completed in 1993 and enrolling 641 patients) demonstrated that compared with placebo, CoQ10 reduced the risk of HF hospitalization (73 versus 118, P<0.001) and complications of HF, such as pulmonary edema and cardiac asthma.
A 2025 RCT demonstrated that CoQ10 supplementation led to significant improvements in several clinical and functional parameters, including a reduction in NT-proBNP levels, improved global longitudinal strain (GLS), increased ejection fraction (EF), and better performance scores for the 6-Minute Walk Test and Minnesota Living with Heart Failure Questionnaire (MLHFQ) compared to a placebo group. These results suggest that CoQ10 may play a beneficial role in improving both cardiac function and quality of life in patients with heart failure.
According to the 2022 ACC/AHA/HFSA guidelines, supplementation with CoQ10 effectively reduced vascular mortality, all-cause mortality, and hospital stays for heart failure at 2 years.
A Cochrane-style review reported inconclusive results on the benefits or harms of coenzyme Q10 in heart failure, noting that existing data were derived from small and heterogeneous trials that focused on physiological measures. Overall, the evidence from large-scale trials such as Q-SYMBIO is considered at least moderate quality, with the most consistent signal being a reduction in major cardiovascular events. Evidence for specific endpoints such as stroke and myocardial infarction remains low quality and inconclusive.
CoQ10 can potentially increase the production of vital antioxidants, such as superoxide dismutase, an enzyme that effectively mitigates vascular oxidative stress in individuals with hypertension. In addition, CoQ10 lowers lipid peroxidation levels by diminishing pro-oxidative compounds. Furthermore, CoQ10 can improve blood flow and safeguard blood vessels by preserving nitric oxide.
There is evidence that CoQ10 supplements can lower blood pressure slightly. A meta-analysis of 12 clinical trials cited in the literature found reductions in both systolic and diastolic blood pressure with CoQ10 supplementation, though effect sizes varied across studies. The overall evidence for blood pressure reduction is promising but is characterized as modest and requires larger, more rigorous trials to establish definitive clinical recommendations.
Statins target the liver and competitively inhibit the enzyme HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Lipid-lowering drugs ("statins") such as lovastatin, simvastatin, pravastatin, and gemfibrozil cause a decrease in serum CoQ10 levels, which might predispose individuals to serious cardiovascular conditions. Statins are effective drugs for lowering hypercholesterolemia and preventing cardiovascular diseases. They can cause various side effects, in particular statin-associated muscle symptoms (SAMS) associated with mitochondrial dysfunction and micronutrient depletion.
The clinical evidence for CoQ10 in SAMS is mixed and reflects the complexity of the subject. A 2025 meta-analysis of seven RCTs with 389 patients in total was included. The selected studies included 35 to 76 patients and had a duration ranging from 30 to 90 days with CoQ10 dosages ranging from 100 to 600 mg per day. Results showed a significant reduction of SAMS in four trials and no significant change in three trials. Overall, a significant reduction in SAMS, measured as pain intensity, after CoQ10 supplementation was found: weighted mean difference (WMD) β0.96 (95% CI β1.88 to β0.03), p < 0.05.
An earlier updated meta-analysis enrolled 12 RCTs with a total of 575 patients (294 in the CoQ10 group and 281 in placebo). Compared with placebo, CoQ10 supplementation ameliorated statin-associated muscle symptoms, including muscle pain (WMD, β1.60; 95% CI, β1.75 to β1.44; P<0.001), muscle weakness (WMD, β2.28; 95% CI, β2.79 to β1.77; P=0.006), muscle cramp (WMD, β1.78; 95% CI, β2.31 to β1.24; P<0.001), and muscle tiredness (WMD, β1.75; 95% CI, β2.31 to β1.19; P<0.001), whereas no reduction in plasma creatine kinase level was observed.
In contrast, a separate meta-analysis did not find benefit for CoQ10 over placebo in improving muscle pain (standardized mean difference, β0.59; 95% CI, β1.54 to 0.36; P = 0.22), concluding that supplementation with CoQ10 did not have any significant benefit in improving statin-induced myopathy.
In summary, evidence on CoQ10 for SAMS is mixed: some meta-analyses suggest a statistically significant reduction in subjective pain scores, while others do not. Studies on its efficacy for statin myopathy have yielded inconsistent results, with some reporting symptom relief and others showing no significant benefit. Larger, well-powered RCTs with standardized muscle-symptom definitions are needed before firm recommendations can be made.
CoQ10 may have applications in migraine therapy due to its potent anti-inflammatory and oxidative stress-reducing properties. Furthermore, by improving mitochondrial function, CoQ10 can contribute to the energy supply to brain cells, which is particularly important in migraine.
Supplementation with CoQ10 in a wide range of doses has resulted in many therapeutic benefits in subjects, including a decrease in the frequency and duration of migraine attacks, a reduction in nausea, a lower maximum pain during an attack, and fewer days with migraine. It seems that CoQ10 may be a relevant therapeutic supplement for the treatment and prevention of migraine.
Based on reviewed studies, CoQ10 may have applications in migraine therapy. Migraine, with a prevalence of 14β15% in the world population, is one of the diseases that markedly reduce patients' quality of life. Several randomized controlled trials have evaluated CoQ10 (including a landmark 2005 RCT by SΓ‘ndor et al. published in Neurology) specifically for migraine prophylaxis and reported reductions in attack frequency. The evidence base is considered preliminary to moderate, given the relatively small sample sizes of individual trials. Evidence strength is characterized as "possibly effective" for migraine prevention.
CoQ10 is an essential cofactor in the mitochondrial respiratory chain, and as a dietary supplement it has gained attention for its potential role in the treatment of neurodegenerative disease. Evidence for mitochondrial dysfunction in neurodegenerative disorders derives from animal models, studies of mitochondria from patients, identification of genetic defects in patients with neurodegenerative disease, and measurements of markers of oxidative stress. Studies of in vitro models of neuronal toxicity and animal models of neurodegenerative disorders have demonstrated potential neuroprotective effects of CoQ10. Several clinical trials of CoQ10 have been performed in Parkinson's disease and atypical Parkinson's syndromes, Huntington's disease, Alzheimer disease, Friedreich's ataxia, and amyotrophic lateral sclerosis, with equivocal findings.
Parkinson's Disease: Some clinical trials in patients suffering from Parkinson's disease suggest that CoQ10 supplementation could delay functional decline. Four randomized, double-blind, placebo-controlled studies comparing CoQ10 treatment in 452 patients at early or mid-stage Parkinson's disease reported improvements in daily activities and other parameters. However, a large Phase III clinical trial (QE3 trial) published in JAMA Neurology in 2014 β a randomized clinical trial of high-dosage CoQ10 in early Parkinson's disease β found no evidence of benefit, and the trial was stopped early for futility.
Huntington's Disease: A multicenter randomized, double-blind, and placebo-controlled trial with CoQ10 in 609 patients with early-stage Huntington's disease did not slow the rate of patients' functional decline. There is not enough evidence to indicate that CoQ10 supplementation can delay the progression of Huntington's disease, at least in its early stages.
General Neurodegeneration: CoQ10 is widely available in multiple formulations and is very well tolerated with minimal adverse effects, making it an attractive potential therapy. Phase III trials of high-dose CoQ10 in large sample sizes are needed to further ascertain the effects of CoQ10 in neurodegenerative diseases.
By regulating oxidative stress and reducing reactive oxygen species (ROS), CoQ10 improves oocyte quality, ovarian function, and mitochondrial efficiency, thereby optimizing assisted reproductive technology (ART) outcomes. Clinical studies demonstrate that CoQ10 supplementation enhances ovarian function, increases the number of eggs, and improves the quality of embryos, particularly in women with weak ovarian reserve functions or older age.
Oxidative stress can damage eggs and sperm. Some research suggests CoQ10 may help stop, and even reverse, the drop in egg quantity and quality as women age. Studies also show that the compound could improve sperm activity and concentration.
There is a need for further studies and clinical trials involving a greater number of participants undergoing longer treatments in order to assess the benefits of CoQ10 treatment in human fertility. The evidence in this domain is therefore currently characterized as preliminary to moderate.
Overall, although the data are inconclusive, they suggest that CoQ10 supplementation may be an interesting molecule in health or disease in individuals without a pathological deficiency and when used for optimizing exercise performance. Considering the results observed in the literature, it is an interesting molecule in sports performance. However, clear approaches should be considered when conducting future research. The overall evidence on exercise performance is mixed and inconclusive, and CoQ10 is not established as a proven ergogenic aid.
The positive effect of CoQ10 has been already demonstrated in mitochondrial syndromes associated with CoQ10 deficiency, inflammation, and cardiovascular diseases as well as in the delay of some age-related processes. Potential positive effects of CoQ10 with regard to kidney disease, fertility, metabolic syndrome, and diabetes have been described. However, more research is needed to validate these observations. Clinical evidence in these areas remains preliminary.
Primary CoQ10 deficiency is a rare autosomal recessive disorder caused by gene defects involved in CoQ biosynthesis with clinical features of steroid-resistant nephrotic syndrome, sensorineural hearing loss (SNHL), optic atrophy, retinopathy, and encephalopathy. CoQ10 replacement therapy is indicated for this rare disorder. High-dose CoQ10 supplementation of 1.2β3 g/day is typically given to adults for deficiency states; however, the efficacy is dependent on the nature of the mutation of the biosynthetic pathway.
Supplements offer CoQ10 in either the oxidized form (ubiquinone) or the reduced form (ubiquinol). The bioavailability of a given CoQ10 supplement depends on the lipid carrier it is immersed in and any added preservatives. Available in various forms, such as tablets, capsules, soft gels, and liquid formulations, these oral supplements range from 30 to 600 mg per unit and are easily accessible over the counter.
CoQ10 is a hydrophobic (lipophilic) molecule with a high molecular weight; absorption of dietary CoQ10 is slow but is improved in the presence of fatty meals. Solubilized CoQ10 formulations provide improved bioavailability, with peak plasma concentrations typically ranging from 5.80 to 8.10 hours, depending on the specific formulation.
Several studies have shown the beneficial effects of dietary CoQ10 supplementation, particularly in relation to cardiovascular health. CoQ10 biosynthesis decreases in the elderly, and consequently, the beneficial effects of dietary supplementation in this population are of greater significance. Given that older adults have increased production of free radicals, suboptimal antioxidant defenses toward free radicals, and a decreased capability to replenish utilized CoQ10, CoQ10 supplementation can be one feasible way to increase CoQ10 status in older adults.
Toxicity is unlikely up to a daily intake of 1,200 mg/day, although typical dosages have been 100 to 200 mg/day. The human supplementation dose of CoQ10 is generally 100 to 300 mg/day. Assuming the human dose is 300 mg/day (5 mg/kg body weight), the safety factor is 60 to 120 times the No-Observed-Adverse-Effect Level (NOAEL) observed in preclinical studies.
CoQ10 is widely available in multiple formulations and is very well tolerated with minimal adverse effects, making it an attractive potential therapy. The most commonly reported adverse effects when they occur are mild gastrointestinal symptoms, including nausea, stomach upset, and loss of appetite.
CoQ10 is chemically similar to vitamin K, which has a pro-coagulant effect, and may theoretically reduce the effect of warfarin. As CoQ10 appears to reduce blood pressure, theoretically there could also be additive effects with anti-hypertensive drugs. Cases where CoQ10 has reduced the effectiveness of warfarin have been reported in the literature, although a double-blind, placebo-controlled crossover trial of 21 patients on long-term stable warfarin treatment did not show any effects of CoQ10 at 100 mg per day for 4 weeks. As a precautionary measure, patients on warfarin should have their warfarin dose monitored more closely if they choose to supplement with CoQ10.
CoQ10 may reduce the effectiveness of certain blood pressure medications or enhance the effects of blood pressure-lowering drugs already being taken, since it has a mild blood pressure-lowering effect of its own.
Beta-blockers (drugs that slow down heart rate and lower blood pressure) could also decrease endogenous CoQ10 levels by inhibition of CoQ10-dependent enzymes. Also, certain oral hypoglycemic agents such as glyburide, acetohexamide, and tolazamide could decrease plasma CoQ10 levels.
There is insufficient clinical research to establish the safety of CoQ10 during pregnancy. Pre-eclampsia is a pregnancy-related condition characterized by hypertension, proteinuria, and oedema. Abnormal CoQ10 levels have been observed in pre-eclampsia. Only one double-blind, placebo-controlled trial has investigated supplementation with CoQ10 at 200 mg per day from week 20 of pregnancy until delivery, in 197 women at increased risk of pre-eclampsia: 25.6% of women in the placebo group and 14.4% of women in the CoQ10 group developed pre-eclampsia. This single trial is preliminary and requires replication.
Although CoQ10 lacks approval from the United States Food and Drug Administration (FDA) for treating any medical condition, it is readily accessible as an over-the-counter dietary supplement and is often recommended by both primary care clinicians and specialists.
Health conditions that CoQ10 (coenzyme Q10) may help support.
CoQ10 is an antioxidant and mitochondrial cofactor studied in ALS because of mitochondrial dysfunction and oxidative stress in disease pathology. In SOD1 transgenic mice, CoQ10 extended survival by 6 days. A Phase II multi-center RCT (n=185) testing doses of 1,800β2,700 mg/day found CoQ10 did not improve ALSFRS-R decline sufficiently to justify a Phase III trial.
CoQ10 plays a critical role in mitochondrial energy production, and its myocardial deficiency is implicated in ischemic heart disease. A 1985 double-blind, placebo-controlled crossover RCT in 12 stable angina patients showed 150 mg/day for 4 weeks significantly increased exercise time (345 to 406 s, p<0.05) and delayed ST-segment depression onset (196 to 284 s, p<0.01). The Linus Pauling Institute lists CoQ10 as potentially improving exercise tolerance and reducing ischemia signs in stable angina.
CoQ10 is a well-established endogenous antioxidant that functions within cell membranes and mitochondria to scavenge reactive oxygen species, protect lipids and proteins from oxidative damage, and upregulate antioxidant enzyme activity. Multiple meta-analyses of randomized controlled trials (RCTs) confirm that CoQ10 supplementation significantly reduces the oxidative stress biomarker malondialdehyde (MDA) and increases total antioxidant capacity (TAC) and superoxide dismutase (SOD) activity in human subjects. The evidence base is clinical and mechanistic, spanning diverse patient populations.
CoQ10 reduces oxidative stress on LDL and supports mitochondrial function in endothelial cells. RCTs combining CoQ10 with AGE showed significant PWV reduction (mean β1.21 m/s). Meta-analyses show CoQ10 may reduce all-cause mortality in heart failure and restore endothelial function in patients on statin therapy, which depletes endogenous CoQ10.
CoQ10 is an endogenous mitochondrial electron carrier proposed to enhance aerobic energy production and reduce exercise-induced oxidative stress. The NIH ODS exercise fact sheet directly addresses CoQ10, finding limited ergogenic benefit and noting one study where CoQ10 groups had smaller power improvements than placebo, suggesting potential interference with training adaptation.
Coenzyme Q10 has been evaluated in multiple meta-analyses of RCTs for blood pressure reduction. A meta-analysis of 12 RCTs found CoQ10 reduced SBP by up to 17 mmHg and DBP by up to 10 mmHg in hypertensive patients. Mechanisms involve antioxidant activity, endothelial function improvement, and enhanced nitric oxide bioavailability.
Multiple RCTs and meta-analyses show CoQ10 supplementation modestly reduces fasting blood glucose and HbA1c, particularly in patients with type 2 diabetes. A 2022 GRADE-assessed meta-analysis of 40 RCTs concluded that 100β200 mg/day provides the greatest glycemic benefit. Results remain somewhat heterogeneous across trials. The primary mechanism is reduction of mitochondrial oxidative stress in pancreatic beta cells and peripheral tissues.
CoQ10 is an essential mitochondrial cofactor that supports ATP production in brain cells, which consume approximately 20% of the body's energy. It also acts as a neuroprotective antioxidant. A meta-analysis found moderate evidence that CoQ10 supplementation (100β400 mg/day) improves general cognitive performance in older adults, and low CoQ10 is associated with cognitive decline and reduced antioxidant defenses.
CoQ10 is an essential mitochondrial electron transport chain component. A 2022 systematic review and meta-analysis of 13 RCTs (n=1,126) found CoQ10 supplementation produced a statistically significant reduction in fatigue scores vs. placebo (Hedges' g=β0.398, p=0.001). Higher daily doses and longer treatment correlated with greater fatigue reduction. Burnout involves genuine mitochondrial stress, making CoQ10 a mechanistically rationale supplement for recovery.
CoQ10 is an essential electron carrier in the mitochondrial electron transport chain, directly facilitating ATP synthesis. Clinical and in vitro studies confirm its role in improving mitochondrial respiration, transmembrane potential, and ATP output. Levels decline with age and statin use, making supplementation broadly relevant to cellular energy support.
CoQ10 is primarily relevant to cholesterol management as an adjunct to statin therapy: statins deplete CoQ10 by up to 40%, and supplementation addresses this deficiency. CoQ10 inhibits LDL oxidation and is included in authoritative cholesterol supplement reviews.
Multiple RCTs demonstrate that CoQ10 supplementation (alone or with NADH) significantly reduces fatigue in chronic fatigue syndrome (ME/CFS) patients. A 2021 RCT of 242 ME/CFS patients showed improved fatigue perception, sleep quality, and health-related quality of life over 12 weeks. CoQ10 deficiency is well-documented in CFS and is mechanistically linked to impaired mitochondrial ATP production.
Multiple randomized controlled trials and meta-analyses provide clinical evidence that CoQ10 supplementation significantly reduces key markers of chronic inflammation, including CRP, TNF-Ξ±, and IL-6. The primary mechanism involves CoQ10's inhibition of NF-ΞΊB-mediated pro-inflammatory gene expression, coupled with its antioxidant activity in the mitochondrial electron transport chain. Results are broadly positive but some heterogeneity exists across trials, and larger studies are still warranted.
Coenzyme Q10 (CoQ10) supplementation has shown efficacy in migraine prevention and fibromyalgia-related chronic pain in multiple clinical trials, including RCTs. It reduces mitochondrial oxidative stress and inflammation. At 150β300 mg/day, it decreases migraine frequency, headache days, and nausea.
CoQ10 (ubiquinone/ubiquinol) supports circulation by improving endothelial function via enhanced nitric oxide bioavailability, reducing oxidative stress in arterial walls, improving vascular tone, and supporting cardiac output in heart failure. Meta-analyses confirm modest blood pressure reductions and improvements in endothelial function. Its levels decline with age and with statin use, making supplementation particularly relevant in cardiovascular populations.
CoQ10 has been investigated in human clinical trials for its potential to support cognitive function and counteract age-related cognitive decline, primarily through its roles as a mitochondrial antioxidant and ATP-production facilitator. Endogenous CoQ10 levels decline with age, and low plasma CoQ10 has been associated with poorer cognitive and executive function in older adults. A 2025 review of 8 human RCTs found mixed results: roughly half showed benefit on cognition while the other half reported no significant improvement. Current evidence is preliminary and insufficient to support CoQ10 as a standard anti-cognitive-decline therapy.
CoQ10 (coenzyme Q10) is a critical mitochondrial electron transport chain component and antioxidant depleted in states of oxidative stress, including post-concussion. Animal TBI studies show CoQ10 administration decreases TBI biomarkers, neuronal loss, and mitochondrial damage. A 2024 meta-analysis (2000β2023 literature) identified CoQ10 as among the nutraceuticals showing promise for TBI management alongside creatine and magnesium. Multiple peer-reviewed reviews support its theoretical and preclinical rationale for concussion recovery.
CoQ10 (ubiquinone) inhibits tyrosinase activity and suppresses MITF-mediated melanin synthesis, making it relevant for pigmentary dark circles. It was included as an active ingredient in a 2025 open-label clinical study (PMC12235579) that achieved a 47.94% reduction in periorbital hyperpigmentation over 6 weeks. A randomized double-blind placebo-controlled study on under-eye dark circles also incorporated CoQ10 as a key active.
CoQ10 (ubiquinone) has been studied as an adjunct for depression, particularly in patients with mitochondrial dysfunction and treatment-resistant depression. A 2021 PMC review identified CoQ10 among agents with evidence for improving depressive symptoms. It reduces oxidative stress, supports mitochondrial energy production, and modulates monoamine levels.
CoQ10 has been studied for dry eye disease through clinical trials showing topical CoQ10 with crosslinked hyaluronic acid improved DED outcomes, reduced all cytokine levels, and elevated total antioxidant status. Histopathological analyses confirmed CoQ10 protects lacrimal gland structure and function from oxidative damage. It is one of ten evidence-supported DED nutrients per a 2024 Frontiers in Pharmacology systematic review.
CoQ10 is an essential component of the mitochondrial electron transport chain and a lipid-soluble antioxidant. A systematic review and meta-analysis of 13 RCTs (n=1,126) found CoQ10 supplementation significantly reduced fatigue scores versus placebo. It is especially relevant for populations with low CoQ10 levels, including older adults and those with chronic fatigue syndrome.
CoQ10 has preclinical and mechanistic evidence supporting its use as adjunctive therapy in epilepsy. Animal studies show CoQ10 reduces seizure severity in PTZ and pilocarpine models, augments the effects of antiepileptic drugs like phenytoin and valproate, and protects against seizure-induced oxidative damage and neuronal loss. CoQ10 deficiency is linked to epileptic manifestations.
CoQ10 is concentrated in sperm mitochondria and acts as both an energy promoter and antioxidant for flagellar movement. Multiple RCTs and a 2025 systematic review and meta-analysis found CoQ10 supplementation significantly increases total sperm count, total and progressive motility, and normal morphology while raising serum testosterone and inhibin B. Standard clinical doses are 100β300 mg/day for 3β6 months.
Multiple RCTs and meta-analyses show CoQ10 supplementation increases clinical pregnancy rates in infertile women undergoing ART, with one meta-analysis (5 RCTs) reporting 28.8% vs. 14.1% clinical pregnancy rate vs. placebo (OR 2.44, 95% CI 1.30β4.59). It reduces reactive oxygen species in oocytes and supports mitochondrial energy production. Evidence is strongest in women with diminished ovarian reserve or poor ovarian response.
CoQ10 deficiency and mitochondrial dysfunction have been documented in FM patients, with tissue CoQ10 levels reportedly 40β50% below normal. A randomized double-blind placebo-controlled trial in 20 FM patients found 300 mg/day CoQ10 for 40 days significantly reduced FIQ scores, pain, fatigue, and tender points versus placebo. A separate randomized crossover study in 22 female FM patients showed CoQ10 improved pain-related outcomes by 24β37% and reduced sleep disturbance by ~33%.
CoQ10 has been investigated for glaucoma neuroprotection based on its mitochondrial bioenergetic and antioxidant functions. Preclinical studies in rodent models of ocular hypertension showed significant neuroprotection of RGCs. Clinical studies demonstrated that topical CoQ10 combined with vitamin E improved PERG amplitudes in POAG patients.
CoQ10 has been evaluated in multiple RCTs as an adjunct to scaling and root planing for periodontitis. A 2025 systematic review and meta-analysis of 10 RCTs found that oral supplementation at 120 mg/day resulted in significantly greater mean reductions in probing pocket depth (0.41 mm) and clinical attachment level gain (0.52 mm) vs. controls. Locally delivered CoQ10 gel also reduces gum bleeding.
Coenzyme Q10 (ubiquinone) has Level C evidence (possibly effective) for migraine prevention per AAN/AHS guidelines. An RCT by SΓ‘ndor et al. (2005, n=42) showed 300 mg/day reduced migraine frequency by 50% in 47.6% of patients vs. 14.4% on placebo. Mitochondrial dysfunction is implicated in migraine pathophysiology and CoQ10 supports mitochondrial energy production.
CoQ10 is an endogenous mitochondrial coenzyme whose levels decline significantly with age, reducing cellular energy production and antioxidant defense. Clinical research links CoQ10 supplementation to improved mitochondrial function, cardiovascular health, and reduced oxidative stress markers. A Frontiers in Physiology review summarizes its role in aging and age-related disease.
Coenzyme Q10 (CoQ10) supports mitochondrial energy production and acts as a powerful antioxidant in cochlear cells. A 2025 double-blind RCT (n=50) found 100 mg/day of CoQ10 significantly decreased tinnitus disability and loudness in presbycusis patients over 6 weeks. A 2007 clinical trial showed benefit for tinnitus patients with low CoQ10 blood levels. A 2026 systematic scoping review identified 14 studies linking CoQ10 to hearing outcomes.
CoQ10 has substantial clinical evidence supporting its role in heart health, particularly in heart failure (HF). As an essential cofactor for mitochondrial ATP production and a potent antioxidant, CoQ10 levels are measurably depleted in HF patients and correlate inversely with disease severity. The landmark Q-SYMBIO randomized controlled trial demonstrated significant reductions in cardiovascular mortality and major adverse cardiac events with supplementation. Evidence also supports benefits in endothelial function, vascular stiffness, and oxidative stress across broader cardiovascular disease contexts.
CoQ10 is a mitochondrial electron carrier reduced in heart disease; its depletion is linked to arrhythmia risk. A meta-analysis of 8 RCTs found cardiac surgery patients treated with CoQ10 were significantly less likely to develop ventricular arrhythmias (OR 0.05, 95% CI 0.01β0.31). Proposed mechanisms include improved cellular energy production, membrane stabilization, and reduced ischemia-induced arrhythmogenesis.
Clinical RCTs demonstrate that CoQ10 supplementation reduces HOMA-IR, a validated index of insulin resistance, in both prediabetic and type 2 diabetic populations. A randomized double-blind placebo-controlled trial of 80 patients with impaired glucose tolerance showed significant HOMA-IR reduction after 8 weeks of CoQ10. The mechanism involves reduced oxidative stress restoring mitochondrial efficiency in insulin-sensitive tissues.
Coenzyme Q10 (ubiquinol/ubiquinone) is an endogenous mitochondrial antioxidant with documented benefits in CKD, where CoQ10 deficiency has been observed. Clinical studies in CKD and hemodialysis patients show CoQ10 supplementation reduces oxidative stress markers, improves mitochondrial function in renal tubular cells, and some trials show modest improvements in creatinine clearance and GFR.
CoQ10 is naturally concentrated in the liver, where it supports mitochondrial energy production and acts as a lipid-soluble antioxidant. Systematic reviews and meta-analyses of RCTs indicate CoQ10 supplementation modestly reduces liver enzymes (ALT and AST) in NAFLD patients. Evidence for broader 'detoxification' is limited to hepatoprotective effects against drug-induced and metabolic liver injury.
CoQ10 is a mitochondrial antioxidant cofactor found in the electron transport chain. A clinical study (Feher 2005) demonstrated that a combination of CoQ10, acetyl-L-carnitine, and omega-3 fatty acids stabilized visual functions in early AMD patients by improving mitochondrial function in the RPE. Reviews of AMD antioxidants consistently identify CoQ10 as effective in improving visual function in early AMD. Typical dose in AMD studies: 50β100 mg/day.
CoQ10 (ubiquinone) is a vital component of the mitochondrial electron transport chain and a potent antioxidant. Clinical studies show CoQ10 supplementation reduces fatigue and may support mental energy, particularly in individuals with CoQ10 deficiency or older adults with declining mitochondrial function.
Multiple randomized controlled trials (RCTs) and meta-analyses demonstrate that CoQ10 supplementation can beneficially modulate key features of metabolic syndrome (MetS), including oxidative stress, inflammation, insulin resistance, and adipokine dysregulation. A 2020 PMC meta-analysis of RCTs (318 participants) found CoQ10 significantly increased adiponectin and lowered inflammation markers in MetS patients. However, effects on individual components such as dyslipidemia, hypertension, and glycemia are inconsistent across trials, and at least one RCT found no significant benefit of CoQ10 alone on MetS components.
CoQ10 is a biochemically essential component of the mitochondrial electron transport chain, directly enabling cellular ATP synthesis via oxidative phosphorylation β making it a foundational element of metabolic energy production. Beyond this core bioenergetic role, CoQ10 participates in fatty acid Ξ²-oxidation, pyrimidine biosynthesis, and gene expression related to cellular metabolism. Clinical trials and meta-analyses document measurable improvements in glycemic markers (fasting glucose, HbA1c, HOMA-IR) in individuals with type 2 diabetes or metabolic syndrome, particularly at doses of 100β200 mg/day. Evidence for broader metabolic benefits (e.g., lipid profiles, oxidative stress reduction) is supported by multiple RCTs, though effect sizes are generally modest.
CoQ10 is supported by Level C evidence (possibly effective) per AAN/AHS guidelines for migraine prevention. A 2024 meta-analysis of RCTs found CoQ10 decreased migraine frequency (MD = β1.73), severity (MD = β1.35), and duration (MD = β1.72). It is well tolerated with few adverse events.
CoQ10 is an essential electron carrier in the mitochondrial respiratory chain and a key component of the inner mitochondrial membrane. Deficiency is directly linked to mitochondrial disease phenotypes including encephalomyopathy and myopathy. Clinical supplementation evidence shows improvements in mitochondrial bioenergetics, physical performance, and quality of life, particularly in aging and primary CoQ10 deficiency syndromes.
CoQ10 is an endogenous mitochondrial electron carrier and lipid-soluble antioxidant. A 2022 PMC systematic review concluded CoQ10 supplementation may offer a favorable profile in controlling oxidative patterns with anti-inflammatory activity at the cellular level in response to exercise, functioning as a protective and recuperative substance.
The most robust clinical evidence concerns statin-associated muscle symptoms (SAMS). Multiple meta-analyses of RCTs show CoQ10 supplementation significantly reduces muscle pain, weakness, cramps, and tiredness in statin-treated patients, though some analyses are discordant. CoQ10 is proposed to restore muscle mitochondrial function depleted by statin-induced CoQ10 reduction.
CoQ10 is an endogenous mitochondrial electron carrier essential for neuronal energy production. It has been clinically studied for neuroprotective effects in Parkinson's disease, migraine prevention, and protection against oxidative stress-mediated neurodegeneration.
Coenzyme Q10 is an endogenous mitochondrial electron carrier essential for ATP synthesis in metabolically demanding nerve cells. Mitochondrial dysfunction is a recognized mechanism in peripheral neuropathy, and CoQ10 supports nerve cell energy production. It is listed in authoritative neuropathy databases and is particularly relevant in statin-associated neuropathy (statins deplete CoQ10) and chemotherapy-induced peripheral neuropathy.
CoQ10 supports nitric oxide (NO) bioavailability by protecting endothelial NO synthase (eNOS) from oxidative inactivation and reducing superoxide-mediated NO degradation. Clinical trials in type 2 diabetes and coronary artery disease patients show improved endothelium-dependent vasodilation (flow-mediated dilation) with CoQ10 supplementation. Evidence from NIH StatPearls lists improving endothelial function as a Level 2 clinical indication.
CoQ10 has been extensively studied in Parkinson's disease based on evidence of mitochondrial Complex I deficiency in PD patients. Phase II trials showed dose-dependent slowing of functional decline; however, a large Phase III RCT (QE3) failed to confirm disease-modifying benefit. Meta-analyses show it is safe but does not significantly improve motor UPDRS scores versus placebo.
CoQ10 is an endogenous antioxidant that has been shown effective for PCOS women undergoing assisted reproductive technologies, reducing insulin resistance, increasing FSH, and improving blood lipids. A meta-analysis confirmed CoQ10 reduces fasting plasma glucose and HOMA-IR and improves sex hormone levels in PCOS.
CoQ10 (ubiquinone/ubiquinol) is essential for mitochondrial electron transport chain function and ATP synthesis, making it directly relevant to physical endurance. A 2022 PMC review of combined CoQ10 supplementation trials found favorable outcomes on physical performance parameters. It has been identified as an IOC-relevant supplement for endurance athletes, and RCTs have shown it supports exercise tolerance and reduces exercise-induced oxidative stress.
CoQ10 is essential for mitochondrial electron transport and ATP production, and its levels are depleted during illness and critical disease states. Post-operative and post-illness recovery protocols specifically include CoQ10 to restore mitochondrial energy production, reduce oxidative stress, and support cardiac function during recovery.
CoQ10 (Coenzyme Q10) is a mitochondrial antioxidant shown to improve patient health both pre- and post-operatively, particularly in cardiac surgery where mitochondrial function is critical. Life Extension's authoritative surgical recovery protocol, citing peer-reviewed research, lists CoQ10 with omega-3 fatty acids and vitamins C, D, and E as improving perioperative health.
CoQ10 is a fat-soluble mitochondrial electron carrier with a direct mechanistic link to post-viral fatigue. Research documents depleted CoQ10 in post-viral syndromes including ME/CFS and long COVID, with clinical trials showing supplementation reduces fatigue and pain in fibromyalgia and related post-viral fatigue conditions. A dedicated 2024 PMC review (PMC10779395) evaluated CoQ10's role in post-viral fatigue syndrome.
Coenzyme Q10 (CoQ10) has been studied for skin aging via topical and oral routes. A randomized trial of 33 patients found oral CoQ10 supplementation for 12 weeks significantly reduced periorbital wrinkles and improved skin smoothness versus placebo. Topical CoQ10 formulations reduce wrinkle depth by stabilizing mitochondrial function and exerting potent antioxidant effects in dermal cells.
CoQ10, in combination with other antioxidants, has been shown in one study to improve respiratory function in men with obstructive sleep apnea. OSA is characterized by oxidative stress from intermittent hypoxia, and CoQ10's established antioxidant and mitochondrial protective properties are mechanistically relevant. OSA patients are at elevated cardiovascular riskβa condition in which CoQ10 supplementation has demonstrated benefit.
Coenzyme Q10 (CoQ10) has been evaluated in meta-analyses for effects on lipid profiles including triglycerides. An umbrella review of meta-analyses (2024) found CoQ10 may have an effect on TG, though results are inconsistent. Strongest evidence is in populations with diabetes or metabolic disorders.
Body systems that CoQ10 (coenzyme Q10) may help support.
Go back